A closer look at CUZD1 (UO-44D): A potential drug target and biomarker for cancer

Target Name: CUZD1

NCBI ID: G50624

CUZD1

A closer look at CUZD1 (UO-44D): A potential drug target and biomarker for cancer

Abstract:
CUZD1 (UO-44D), a glycoprotein-like molecule, has been identified as a potential drug target and biomarker for cancer. Its unique structure and various post-translational modifications (PTMs) make it an attractive target for small molecule inhibitors. This article provides an overview of CUZD1, its potential drug targeting properties, and its potential as a biomarker for cancer.

Introduction:
Cancer is a leading cause of death worldwide, with over 20 million new cases being diagnosed each year. The development of new treatments is crucial for improving cancer treatment outcomes. One of the promising avenues for cancer research is the discovery of potential drug targets and biomarkers. CUZD1 (UO-44D), a glycoprotein-like molecule, has been identified as a potential drug target and biomarker for cancer.

Structure and Function:
CUZD1 is a 44 kDa protein that contains four unique post-translational modifications (PTMs): N-terminal hyper-expression, N-terminal phosphorylation, N-terminal ubiquitination, and N-terminal citrinization. The N-terminal hyper-expression is a result of a unique N-terminal insertion of a 13 amino acid residue at its position. The N-terminal phosphorylation and ubiquitination result in the formation of a N-terminal fragment that can be targeted by small molecules. The N-terminal citrinization results in the formation of a citrinylated terminal that may enhance protein stability.

CUZD1 functions as a cell adhesion molecule, promoting the formation of tight junctions and maintaining tissue barrier integrity. It is also involved in cell signaling, playing a role in the regulation of cell cycle progression and apoptosis. The unique structure of CUZD1, with its four PTMs, makes it an attractive target for small molecule inhibitors.

Potential Drug Targeting:
CUZD1's unique structure and PTMs make it an attractive target for small molecule inhibitors. The N-terminal hyper-expression and phosphorylation result in the formation of a N-terminal fragment that can be targeted by small molecules. The N-terminal ubiquitination and citrinization may also enhance protein stability, providing additional targets for small molecules.

In addition to its potential as a drug target, CUZD1 has also been identified as a potential biomarker for cancer. Its unique structure and various PTMs make it a potential diagnostic tool for cancer. For example, changes in CUZD1 levels may indicate the presence of cancer cells, making it a promising biomarker for cancer detection.

CUZD1 has also been shown to play a role in cancer progression and metastasis. It has been shown to be involved in the regulation of cell migration and the formation of cancer cell-rich microenvironment, further supporting its potential as a biomarker for cancer.

Conclusion:
In conclusion, CUZD1 (UO-44D) is a promising drug target and biomarker for cancer. Its unique structure and various PTMs make it an attractive target for small molecule inhibitors. Further research is needed to fully understand CUZD1's role in cancer and its potential as a diagnostic tool.

Protein Name: CUB And Zona Pellucida Like Domains 1

Functions: Localized to zymogen granules, where it functions in trypsinogen activation (By similarity). May indirectly regulate cell motility, cell-cell and cell/extracellular matrix interactions (PubMed:15184879)

The "CUZD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CUZD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets